CA2333320A1 - Traitement de l'infertilite par des composes stimulant la production d'ampc, seuls ou associes a au moins un compose stimulant la meiose - Google Patents

Traitement de l'infertilite par des composes stimulant la production d'ampc, seuls ou associes a au moins un compose stimulant la meiose Download PDF

Info

Publication number
CA2333320A1
CA2333320A1 CA002333320A CA2333320A CA2333320A1 CA 2333320 A1 CA2333320 A1 CA 2333320A1 CA 002333320 A CA002333320 A CA 002333320A CA 2333320 A CA2333320 A CA 2333320A CA 2333320 A1 CA2333320 A1 CA 2333320A1
Authority
CA
Canada
Prior art keywords
meiosis
compound
increasing
use according
stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002333320A
Other languages
English (en)
Inventor
Christa Hegele-Hartung
Quoc-Lam Cam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2333320A1 publication Critical patent/CA2333320A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique qui renferme des composés stimulant la production d'AMPc à faible dose et au moins un composé stimulant la méiose, et qui permet de traiter l'infertilité. Elle concerne également l'utilisation desdits composés stimulant la production d'AMPc, seuls ou associés à au moins un composé stimulant la méiose, afin d'augmenter le taux de fécondité chez un mammifère et de préparer des médicaments.
CA002333320A 1998-05-26 1999-05-07 Traitement de l'infertilite par des composes stimulant la production d'ampc, seuls ou associes a au moins un compose stimulant la meiose Abandoned CA2333320A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98250177.7 1998-05-26
EP98250177 1998-05-26
PCT/EP1999/003138 WO1999061010A2 (fr) 1998-05-26 1999-05-07 TRAITEMENT DE L'INFERTILITE PAR DES COMPOSES STIMULANT LA PRODUCTION D'AMPc, SEULS OU ASSOCIES A AU MOINS UN COMPOSE STIMULANT LA MEIOSE

Publications (1)

Publication Number Publication Date
CA2333320A1 true CA2333320A1 (fr) 1999-12-02

Family

ID=8234594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002333320A Abandoned CA2333320A1 (fr) 1998-05-26 1999-05-07 Traitement de l'infertilite par des composes stimulant la production d'ampc, seuls ou associes a au moins un compose stimulant la meiose

Country Status (7)

Country Link
EP (1) EP1098652A2 (fr)
JP (1) JP2002516272A (fr)
KR (1) KR20010043828A (fr)
AU (1) AU5408999A (fr)
CA (1) CA2333320A1 (fr)
NO (1) NO20005954D0 (fr)
WO (1) WO1999061010A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019354A2 (fr) 1999-09-16 2001-03-22 Novo Nordisk A/S Composition pour fecondation in vitro
US6544166B1 (en) 1999-11-25 2003-04-08 Groendahl Christian Treatment of human infertility
WO2001038493A1 (fr) * 1999-11-25 2001-05-31 Novo Nordisk A/S Traitement de l'infertilite humaine
AU2001240624A1 (en) * 2000-02-25 2001-09-03 Novo-Nordisk A/S Improvement of implantation rate
WO2001062260A2 (fr) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Amelioration d'un taux d'implantation
WO2001076360A2 (fr) * 2000-04-06 2001-10-18 Novo Nordisk A/S Synchronisation de la maturation nucleaire et cytoplasmique d'oocytes in vitro
EP1147774A1 (fr) 2000-04-20 2001-10-24 Stichting Dienst Landbouwkundig Onderzoek Méthode d'amélioration de la qualité du sperme pour l'insémination artificielle des animaux
JP2003533222A (ja) * 2000-05-18 2003-11-11 シエーリング アクチエンゲゼルシャフト 経年卵母細胞の受精
EP1245572A1 (fr) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Composés aminostérols, leur utilisation pour la préparation des médicaments pour la régulation de la méiose et un procédé de leur préparation
IL162506A0 (en) 2001-12-14 2005-11-20 Applied Research Systems Ovulation induction
WO2003070766A2 (fr) * 2002-02-22 2003-08-28 Novo Nordisk A/S Transducteur de la signalisation de mas
EP2750692B1 (fr) 2011-08-30 2016-08-03 Centre National De La Recherche Scientifique Complexe protéinique comprenant des protéines mcm8 et mcm9 et leur utilisation
GB201117453D0 (en) * 2011-10-10 2011-11-23 Univ Dundee Improved sperm function/activity
CN108531447B (zh) * 2018-04-13 2021-11-23 上海市生物医药技术研究院 调节精子运动能力及辅助生殖的化合物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196530A3 (fr) * 1985-03-26 1989-03-22 CTA Finanz AG Agent et procédé pour augmenter la croissance, optimiser la fécondité et stimuler le système immunitaire chez les humains et les animaux
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols
KR19980702624A (ko) * 1995-03-06 1998-08-05 슈타르 피아 감수분열의 자극
US5800625A (en) * 1996-07-26 1998-09-01 Cauldron Limited Partnership Removal of material by radiation applied at an oblique angle
CA2199663C (fr) * 1997-03-11 2004-08-10 Ruth Miriam Moses Maturation et fecondation in vitro d'ovocytes mammaliens

Also Published As

Publication number Publication date
WO1999061010A2 (fr) 1999-12-02
WO1999061010A3 (fr) 2000-04-27
KR20010043828A (ko) 2001-05-25
JP2002516272A (ja) 2002-06-04
NO20005954L (no) 2000-11-24
AU5408999A (en) 1999-12-13
EP1098652A2 (fr) 2001-05-16
NO20005954D0 (no) 2000-11-24

Similar Documents

Publication Publication Date Title
CA2333320A1 (fr) Traitement de l'infertilite par des composes stimulant la production d'ampc, seuls ou associes a au moins un compose stimulant la meiose
AU764452B2 (en) Method of promoting cervical and vaginal secretions
US5830757A (en) Stimulation of Meiosis
EP1156821B1 (fr) Traitement de l'infecondite
JP2001500865A (ja) 避妊の非ホルモン法
US6585982B1 (en) Treatment of infertility
US20080311656A1 (en) Meiosis arrest in oocytes in vitro
Tsafriri et al. Is meiosis activating sterol (MAS) an obligatory mediator of meiotic resumption in mammals
EP1235899B1 (fr) Traitement de l'infertilite humaine
Heath et al. Fluoropyrimidine treatment of ocular cicatricial disease.
Uche‐Nwachi Effect of intramuscular sulfadoxine‐pyrimethamine on pregnant Wistar rats
US6544166B1 (en) Treatment of human infertility
Roy et al. In vitro inhibition of trophoblast maturation and expansion of early rat blastocysts by an oestrogen antagonist
MXPA00009505A (en) TREATMENT OF INFERTILITY WITH cAMP-INCREASING COMPOUNDS ALONE OR IN COMBINATION WITH AT LEAST ONE MEIOSIS-STIMULATING COMPOUND
WO2001062260A2 (fr) Amelioration d'un taux d'implantation
EP1272618A2 (fr) Synchronisation de la maturation nucleaire et cytoplasmique d'oocytes in vitro
WO1997000883A1 (fr) Composes regulateurs de la meiose
US20030153808A1 (en) Implantation rate using ff-mas
EP1285058A2 (fr) Fertilisation d'oocytes ages
AU4498299A (en) Meiosis regulating compounds
EP1664079B1 (fr) Composes thiomorpholino steroides, leur utilisation pour la preparation de medicaments regulant la meiose et procede de preparation associe
MXPA97006565A (es) Estimulacion de meiosis
MXPA06001145A (en) Thiomorpholino steroid compounds, the use thereof for the preparation of meiosis-regulating medicaments and method for the preparation thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead